Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

BioNexus Gene Lab Corp

BGLCNASDAQEQUITYCurrent

Other Events

Item 8.01. Other Events On May 29, 2026, BioNexus Gene Lab Corp. (the “Company”) issued a press release titled “BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Cooperation to Move Beyond Trade into Co-Development,” highlighting the Company’s participation in the 2026 China-Malaysia Economic Cooperation Outlook Forum held on May 21, 2026 in Kuala Lumpur, Malaysia, and the Company’s v…

Filed Jun 5, 2026Accepted Jun 5, 2026, 9:00 AM EDTCIK 1737523Accession 0001477932-26-003658
Share

Company context

BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology-focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life-science businesses alongside its established operations.

Current securities

Recent company filings

  1. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 7, 2026
  2. SCHEDULE 13D - filed by Tan Lee Su-Leng regarding BioNexus Gene Lab CorpAug 14, 2026
  3. 10-Q filingAug 14, 2026
  4. Other EventsJul 28, 2026
  5. 10-Q filingMay 15, 2026

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events On May 29, 2026, BioNexus Gene Lab Corp. (the “Company”) issued a press release titled “BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Cooperation to Move Beyond Trade into Co-Development,” highlighting the Company’s participation in the 2026 China-Malaysia Economic Cooperation Outlook Forum held on May 21, 2026 in Kuala Lumpur, Malaysia, and the Company’s views regarding Malaysia-China biotechnology cooperation, precision healthcare collaboration, cross-border biotechnology commercialization and related platform-building opportunities. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description ──────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release dated May 29, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Filed exhibits (1)
EX-99.1 (by filename) bglc_ex991.htm

EX-99.1 2 bglc_ex991.htm PRESS RELEASE bglc_ex991.htm EXHIBIT 99.1 BioNexus Gene Lab Corp. Calls for Malaysia - China Biotechnology Cooperation to Move Beyond Trade into Co-Development KUALA LUMPUR, Malaysia, May 29, 2026 - BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China - Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur. The forum, held under the theme “Advancing Biotechnology and Healthcare Collaboration towards a China - Malaysia Community with a Shared Future,” brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and China to discuss strategic cooperation across biotechnology, healthcare, pharmaceutical development, infrastructure, and related sectors. Sam Tan, Chief Executive Officer of BioNexus, participated as a speaker, where he discussed the opportunity to build a Malaysia - China precision healthcare corridor focused on moving…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.